Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD

This real-world study evaluated the efficacy of once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for improving lung function in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD who were treated with once-da...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei-Chun, Chen, Chih-Yu, Liao, Wei-Chih, Wu, Biing-Ru, Chen, Wei-Chun, Tu, Chih-Yen, Chen, Chia-Hung, Cheng, Wen-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739795/
https://www.ncbi.nlm.nih.gov/pubmed/36498738
http://dx.doi.org/10.3390/jcm11237165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739795/
https://www.ncbi.nlm.nih.gov/pubmed/36498738
http://dx.doi.org/10.3390/jcm11237165

Ejemplares similares